PDA

View Full Version : Pinnacle(TM) Hip Solutions With Trueglide(TM) Technology



Medical Videos
03-16-2008, 08:58 PM
DePuy Orthopaedics, Inc., a global leader in devices for joint replacement, announced the launch of Pinnacle™ Hip Solutions with TrueGlide™ technology, a portfolio of high performance instruments, advanced implants, materials and solutions. Pinnacle Hip Solutions products are designed to promote pain relief and a smooth range-of-motion. This new portfolio of hip products offers surgeons more options and greater flexibility when performing hip replacement surgery.

DePuy announced the company will also be launching a professional and consumer education campaign about the science and clinical evidence behind the products. This campaign will feature actual hip replacement patients, including legendary Duke Basketball head coach Mike (Coach K) Krzyzewski, who has two DePuy hips.

DePuy Orthopaedics made the announcement here at the 75th Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS), where it will showcase the new Tri-Lock™ Bone Preservation Stem, AltrX™ LD liners and Biolox™ Delta TS ceramic heads, all being introduced under the Pinnacle Hip Solutions banner.

"Pinnacle Hip Solutions is built for modern hip replacement patients who want long lasting pain relief, a more fluid range of natural movement and a quicker recovery so they can enjoy life again," said David Floyd, president of DePuy Orthopaedics. "DePuy Orthopaedics will continue to advance the art and science of hip replacement with products that help surgeons optimize patient outcomes."

At AAOS, DePuy Orthopaedics featured the Tri-Lock® Bone Preservation Stem, a new Tapered-Wedge titanium stem that minimizes the amount of bone that needs to be removed during hip replacement surgery, while promoting stability, preserving the natural anatomy and restoring hip function.

The Tri-Lock Bone Preservation Stem has a reduced lateral shoulder, narrow geometry and optimized length and can be used with minimally invasive techniques. Also, Tri- Lock is coated with Gription™ fixation technology, a coating that provides consistent implant seating height and improved initial stability and maximizes the potential for longterm bony growth.

AltrX LD large diameter polyethylene liners and Biolox Delta TS ceramic heads were also introduced, offering surgeons new choices for optimizing stability, reducing wear, and providing greater longevity.

About Hip Replacement

According to the AAOS, the demand for hip replacement is growing rapidly. It is estimated that the number of primary total hip replacements will increase by 174 percent -- to 572,000 -- in 2030.1 This is due in part to the growing number of Baby Boomers with osteoarthritis and the rise in obesity. For more information about hip replacement visit DePuy's Web site http://www.hipreplacement.com (http://www.hipreplacement.com/).

About DePuy Orthopaedics, Inc.

DePuy Orthopaedics, Inc., a Johnson & Johnson company, is advancing the standard of orthopaedic patient care, with a focused commitment to help surgeons achieve excellence in surgical practice. The company designs, manufactures and distributes orthopaedic devices and supplies including hip, knee, extremity, trauma, cement, orthobiologics, and operating room products. As a global leader in joint replacement products, DePuy Orthopaedics is committed to Restoring the Joy of Motion® for patients whose mobility is restricted by severe osteoarthritis or other debilitating injury. For more information about DePuy Orthopaedics, Inc., visit the company's Web site http://www.depuyorthopaedics.com (http://www.depuyorthopaedics.com/).

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Johnson & Johnson's expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of the Company's Annual Report on Form 10-K for the fiscal year ended December 30, 2007. Copies of this Form 10-K, as well as subsequent filings, are available online at http://www.sec.gov (http://www.sec.gov/), http://www.jnj.com (http://www.jnj.com/) or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.

Reference:

1. "Total Knee and Hip Replacement Surgery Projections Show Meteoric Rise by 2030. Orthopaedic procedures set to continue gaining widespread acceptance as means to restore quality-of-life," American Academy of Orthopaedic Surgeons (AAOS) Web site: see here. (http://www6.aaos.org/news/Pemr/press_release.cfm?PRNumber=442)

DePuy Orthopaedics, Inc. (http://www.depuyorthopaedics.com/)